Advancing Cancer Therapy
Cancer Advances is a biotechnology company focused on impacting human health and the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio.
Cancer Advances is dedicated to enhancing the immune system and augmenting
human quality of life by targeting the progression of gastrointestinal cancers.
Cancer Advances is a wholly owned subsidiary of Cato BioVentures. The company's lead compound, Polyclonal Antibody Stimulator (PAS), is an immunomodulator used to treat gastrointestinal cancer. Please visit our Product page for more information on what is in development.